|
|
|
FDA Home Page | Search FDA Site | FDA A-Z Index | Contact FDA
| Center | Date | Time | Location |
|---|---|---|---|
| CDER | May 3, 2004 May 4, 2004 |
8 a.m. - 5 p.m. 8 a.m. - 5 p.m. |
Hilton |
Agenda:
On May 3, 2004, the committee will discuss these items: (1) New drug application
(NDA) 21-649, GENASENSE (oblimersen sodium) Genta, Inc., proposed indication
for use in combination with DTIC DOME (dacarbazine), Bayer Pharmaceuticals Corp.,
proposed for the treatment of patients with advanced malignant melanoma.; and
(2) NDA 21-661, RSR 13 Injection (efaproxiral sodium) AlIos Therapeutics, Inc.,
proposed indication for use as an adjunct to whole brain radiation therapy in
the treatment of brain metastases from primary breast cancer.
On May 4, 2004, the committee will discuss these items: (1) Safety concerns associated with ARANESP (darbepoetin alfa) Amgen, Inc., and PROCRIT (epoetin alfa) Ortho Biotech, L.P., both of which are indicated for the treatment of anemia associated with cancer chemotherapy; and (2) colo-rectal cancer endpoints as a followup to the November 2003 FDA Workshop.
Background material and meeting information will become available no later than the day before the meeting (Simply select the appropriate committee link).
Procedure:
Interested persons may present data, information, or views, orally or in writing,
on issues pending before the committee. Written submissions may be made to the
contact person by April 26, 2004. Oral presentations from the public will be
scheduled between approximately 10:30 a.m. and 11 a.m., and 2:30 p.m. and 3
p.m on May 3, 2004. On May 4, 2004, oral presentations from the public will
be scheduled between approximately 10:30 a.m. and 11 a.m., and 2:30 p.m. and
3 p.m. Time allotted for each presentation may be limited. Those desiring to
make formal oral presentations should notify the contact person before April
26, 2004, and submit a brief statement of the general nature of the evidence
or arguments they wish to present, the names and addresses of proposed participants,
and an indication of the approximate time requested to make their presentation.
Persons attending FDA's advisory committee meetings are advised that the agency
is not responsible for providing access to electrical outlets.
FDA welcomes the attendance of the public at its advisory committee meetings
and will make every effort to accommodate persons with physical disabilities
or special needs. If you require special accommodations due to a disability,
please contact Trevelin Prysock at 301-827-7001, at least 7
days in advance of the meeting.
Contact Person:
Johanna M. Clifford, Center for Drug Evaluation and Research (HFD-21), Food
and Drug Administration, 5600 Fishers Lane (for express delivery, 5630 Fishers
Lane, rm. 1093) Rockville, MD 20857,301-827-7001, FAX: 301-827-6776 or e mail:
cliffordj@cder.fda.gov, or FDA Advisory
Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington,
DC area), code 3014512542. Please call the Information Line for up-to-date information
on this meeting.
[ Full FR Notice ]